Substituted fused heterocycles as c-Met tyrosine kinase inhibitors

US9242991B2 · kind B2 · utility

Assignee

• Betta Pharmaceuticals Co., Ltd · CN

Inventors

• Shaojing Hu · Beijing, CN
• Fei Wang · Beijing, CN
• Wei Long · Beijing, CN
• Xiaoyan Shen · Beijing, CN
• Fenlai Tan · Beijing, CN
• Yinxiang Wang · Beijing, CN

Key dates

• Filing date: Jul 14, 2011
• Grant date: Jan 26, 2016
• Expiry date: Jul 14, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to certain novel fused quinazoline derivatives (Formula I) as c-Met inhibitors which is shown as formula I, their synthesis and their use for treating a c-Met mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful inhibitors of c-Met, methods for producing such compounds and methods for treating as c-Met mediated disorder